The Dana-Farber Cancer Institute is running a clinical trial to evaluate the effectiveness (how well the drug/s work) of nivolumab combined with ipilimumab, two types of immunotherapy. Both the two drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of several cancers. The combination has been approved by FDA as treatment for metastatic melanoma. Yet the use of nivolumab as well as ipilimumab alone or in combination for the treatment of patients with thyroid cancer is not approved.
Drugs are Nivolumab & Ipilimumab.
|Study Type :
||Interventional (Clinical Trial)
|Estimated Enrollment :
||None (Open Label)
||A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer
|Actual Study Start Date :
||September 20, 2017
|Estimated Primary Completion Date :
||March 31, 2021
|Estimated Study Completion Date :
||March 31, 2025
For enrollment please visit www.clinicaltrials.gov.
Patricia McHugh, BSN 617-632-3090 [email protected]
Michelle Flynn, BSN 617-632-3090 [email protected]
Reference Code: NCT03246958